INVINCIBLE-3NCT06263231
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 37 words
- Trial sites expanded: 17 → 20 locations
- Collaborator revised
- Publications: details revised at 20 of 21 entries
- Notable Enrollment reopened
- Site details revised at 17 of 17 sites
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 17 of 17 sites
- Minor Study sites: 15 to 17v9
- Minor Study sites: 13 to 15v8
Show 6 earlier versionsHide 6 earlier versions
- Minor Study sites: 10 to 13v7
- Minor Study sites: 9 to 10v6
- Minor Study sites: 4 to 9v5
- Notable Eligibility criteria shortened, about 51 words
- Study sites: 1 to 4
- Study title expanded, about 1 word
- Minor Start date changed from estimate of Jun 2024 to Jun 28, 2024v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (2)
Arms and interventions
INT230-6 administered intratumorally. Participants will be dosed every 2 weeks (± 2 days) for up to a total of 5 treatment sessions (e.g., Days 1, 15, 29, 43 and 57). Once the participant has completed the treatment phase, they will continue into a 22-month maintenance phase, where investigators may inject new lesions or previously injected lesions with up to 175 mL of INT230-6 every 12 weeks (Q12W) ± 14 days. Dose volume in a session is dependent on the participants presenting tumor burden.
Participants in this arm may receive any of the following depending on soft tissue sarcoma (STS) subtype and PI preference: * Pazopanib: 800 mg PO every day until clinical deterioration or disease progression * Trabectedin: 1.5 mg/m2 body surface area as 24-hour IV infusion every 3 weeks until clinical deterioration or disease progression * Eribulin: Non- European Union (EU) sites: 1.4 mg/m2 eribulin mesylate body surface area IV on Days 1 and 8 every 3 weeks until clinical deterioration or disease progression EU sites: 1.23 mg/m2 (free base) body surface area IV on Days 1 and 8 every 3 weeks until clinical deterioration or disease progression
Drugs: INT230-6, Eribulin, Trabectedin, Pazopanib
Sites
20 sites in 5 countries
United States 13, Spain 3, Germany 2, Canada 1, France 1